Radoslaw Madry

Poznan, WP 61701, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Immune-Related Adverse Events of Cemiplimab Therapy in Advanced Cervical Cancer-Data from the Polish-Czech Cervical Cancer Immunotherapy Group (PCCIG-01) with a Review of the Literature.

Immune-Related Adverse Events of Cemiplimab Therapy in Advanced Cervical Cancer-Data from the Polish-Czech Cervical Cancer Immunotherapy Group (PCCIG-01) with a Review of the Literature.

Journal: Antibodies (Basel, Switzerland)

Published: March 26, 2026

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: November 17, 2025

Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial.

Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial.

Journal: Trials

Published: April 17, 2025

Thyroid disorders as predictors of cemiplimab efficacy in recurrent/metastatic cervical cancer: real-world evidence from Poland.

Thyroid disorders as predictors of cemiplimab efficacy in recurrent/metastatic cervical cancer: real-world evidence from Poland.

Journal: Frontiers in immunology

Published: April 02, 2025

Real-world outcomes of immune checkpoint inhibitor monotherapy in later lines of recurrent/metastatic cervical cancer - evidence from a rescue access program in Poland.

Real-world outcomes of immune checkpoint inhibitor monotherapy in later lines of recurrent/metastatic cervical cancer - evidence from a rescue access program in Poland.

Journal: Contemporary oncology (Poznan, Poland)

Published: March 14, 2025

Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial.

Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial.

Journal: Gynecologic oncology

Published: February 03, 2025

Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in 2018-2023 and the Impact of Molecular Diagnostics on Chemotherapy in Clinical Practice.

Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in 2018-2023 and the Impact of Molecular Diagnostics on Chemotherapy in Clinical Practice.

Journal: Biomedicines

Published: January 02, 2025

Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.

Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 18, 2024

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 12, 2024

Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status.

Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status.

Journal: British journal of cancer

Published: August 01, 2024

Olaparib-induced hyperglycemia in ovarian cancer patients - a case series analysis of a three-month therapy with a consideration of BMI.

Olaparib-induced hyperglycemia in ovarian cancer patients - a case series analysis of a three-month therapy with a consideration of BMI.

Journal: Pharmacological reports : PR

Published: June 06, 2024

Symptomatic malignant ascites drainage with a patient-controlled vascular catheter: interim analysis of safety and patient-reported outcomes.

Symptomatic malignant ascites drainage with a patient-controlled vascular catheter: interim analysis of safety and patient-reported outcomes.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: April 14, 2024

Showing 1-12 of 48

Last Updated: 09/26/2026